Journal of the American Academy of Child & Adolescent Psychiatry
Volume 44, Issue 8 , Pages 829-832 , August 2005

Pharmacological Management of Agitation and Aggression in an Adolescent With Autism

,Accepted 28 March 2005.

REFERENCES 

  1. American Diabetes Association  , American Psychiatric Association  , American Association of Clinical Endocrinologists  , North American Association for the Study of Obesity  . Consensus development conference on antipsychotic drugs and obesity and diabetes . Diabetes Care . 2004;27:596–601
  2. Findling RL , McNamara NK , Gracious BL , et al.   Quetiapine in nine youths with autistic disorder . J Child Adolesc Psychopharmacol . 2004;14:287–294
  3. Lieberman J . Quetiapine . In:  Schatzberg A ,  Nemeroff C editor. The American Psychiatric Publisher's Textbook of Psychopharmacology . 3rd ed.. Arlington, VA: American Psychiatric Press; 2004;p. 473–486
  4. Martin A , Koenig K , Scahill L , Bregman J . Open label quetiapine in the treatment of children and adolescents with autistic disorder . J Child Adolesc Psychopharmacol . 1999;9:99–107
  5. McDougle CJ , Posey DJ . Autistic and other pervasive developmental disorders . In:  Martin A ,  Scahill L ,  Charney DS ,  Leckman JF editor. Pediatric Psychopharmacology: Principles and Practice . New York: Oxford University Press; 2003;p. 563–579
  6. Research Units on Pediatric Psychopharmacology Autism Network  . Risperidone in children with autism and serious behavioral problems . N Engl J Med . 2002;347:314–321
  7. Shea S , Turgay A , Carroll A , et al.   Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders . Pediatrics . 2004;114:e634–e641

 Dr. Kratochvil is supported by grant 5K23MH06612701A1 from the National Institute of Mental Health.Based on a topic suggested by Derek Richardson, M.D., and Martin Drell, M.D. Case vignette created to exemplify a complex clinical problem and does not refer to any specific patient.This column aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The cases and discussions specifically target aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with complex, severe, and comorbid disorders, recommendations are likely to be “off label” from the perspective of the U.S. Food and Drug Administration (FDA). We fully appreciate that for virtually all disorders medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. The responses from the expert clinicians are not meant to be practice guidelines but rather examples of thought processes that may go into pharmacotherapy decision making.Disclosure: Dr. Kratochvil has received grant support from or been a consultant and/or member of a speaker's bureau for Eli Lilly, GlaxoSmithKline, Forest, Cephalon, Novartis, McNeil, Organon, AstraZeneca, and Pfizer. Dr. Findling receives or has received research support from or been a consultant and/or member of a speaker's bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Forest, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, New River, Novartis, Otsuka, Pfizer, Shire, Solvay, and Wyeth. Dr. McDougle has received grant support from or been a consultant and/or member of a speaker's bureau for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen Pharmaceutical, PediaMed Pharmaceuticals, and Pfizer. Dr. Scahill has consulted for Janssen Pharmaceutical, Pfizer, and Bristol-Myers Squibb. Dr. Hamarman has received grant support from or been a consultant and/or member of a speaker's bureau for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen Pharmaceutical, McNeil, Orphan Medical, and UCB-Pharma.

PII: S0890-8567(09)61745-7

doi: 10.1097/01.chi.0000166380.68392.4b

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 44, Issue 8 , Pages 829-832 , August 2005

Article Tools